Vicky Lynn Norris, DO | |
6105 Wilson Ave Sw, Grandville, MI 49418-9714 | |
(616) 391-2778 | |
(616) 486-5076 |
Full Name | Vicky Lynn Norris |
---|---|
Gender | Female |
Speciality | Emergency Medicine |
Location | 6105 Wilson Ave Sw, Grandville, Michigan |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1164457917 | NPI | - | NPPES |
11284828 | Other | CAQH PROVIDER ID | |
0156910165 | Other | MI | BCBSM |
1164457917 | Medicaid | MI | |
700C910950 | Other | MI | BCBSM |
4606954 | Medicaid | MI |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | 5101011342 (Michigan) | Primary |
Mailing Address | Practice Location Address |
---|---|
Vicky Lynn Norris, DO 100 Michigan St Ne, Mc 845, Grand Rapids, MI 49503-2560 Ph: (616) 391-2778 | Vicky Lynn Norris, DO 6105 Wilson Ave Sw, Grandville, MI 49418-9714 Ph: (616) 391-2778 |
News Archive
Wake Forest Baptist Medical Center researchers seeking a successful treatment for traumatic brain injury have found that the size and extent of damaged tissue can be reduced by using a new device to prevent cell death.
EBiothera's Phase II non-small cell lung cancer (NSCLC) clinical trial evaluating Imprime PGG administered in combination with cetuximab (Erbitux), carboplatin and paclitaxel has met its goal of 90 patients and is fully enrolled, the company announced today.
Cardiac Dimensions, Inc. announced today the initiation of two new clinical studies using the CARILLON Mitral Contour System, an investigational device for percutaneous treatment of Functional Mitral Regurgitation.
More than one third of patients with invasive cancer are undertreated for their pain, with minorities twice as likely to not receive analgesics, according to research from The University of Texas MD Anderson Cancer Center.
The Medicines Company today announced the publication of the results from the SOLO I Phase 3 clinical trial of ORBACTIV (oritavancin), an investigational intravenous antibiotic treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), in the New England Journal of Medicine.
› Verified 7 days ago